DAROLUTAMIDE (has an active metabolite) | DAROLUTAMIDE | ATC L02BB06
ANTINEOPLASTIC ANDROGEN RECEPTOR INHIBITOR TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | ORAL | Cmax 12 MICROMOLAR Tmax 4 HOUR F 30 PERCENT VD 119 LITER PPB 92 PERCENT Cl 6.96 LITER / HOUR HT 20 HOUR SOLUBILITY PRACTICALLY INSOLUBLE IN AQUEOUS MEDIUM | ANDROGEN RECEPTOR (AR) | Androgen receptor UNIPROT P10275 AR more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |